Lieff Cabraser partners Brendan Glackin and Katharina Kolb will be taking part in the American Bar Association Antitrust Law Section program, “Collective Actions in Europe: An Update,” on Thursday, June 10, 2021 at 12 PM EDT. Brendan will serve as the event moderator, and Katharina will participate as a featured panelist.
The program will survey the different applications of the Damages Directive and Collective Redress Guidance across member states, and parallel developments in the U.K. The program will note jurisdictions that present particular opportunities for civil plaintiffs and corresponding risks for defendants. After a primer on general policies, issues of focus will be damages, pass-on, and retroactivity.
For more information and to register, visit the ABA’s website.
About Brendan P. Glackin
The Chair of Lieff Cabraser’s Antitrust practice group, San Francisco partner Brendan P. Glackin has represented direct purchasers of titanium dioxide in a nationwide antitrust class action lawsuit ($163.5 million in settlements); direct purchasers of flat-panel TV screens in litigation against the world’s leading LCDs manufacturers for conspiring to fix prices ($470 million in settlements; retailers in a monopolization pricing lawsuit against Abbott Laboratories charging that the company exploited the market for AIDS medicines used in conjunction with Abbott’s prescription drug Norvir, and employees in the high-tech workers class action alleging that major Silicon Valley firms colluded to reduce competition for workers.
Brendan has contributed groundbreaking work in litigation against drug makers for blocking access to affordable generics. This includes the blockbuster brand-name prescription drug Cipro ($399 million in settlements), which led to a 2016 “California Lawyer Attorney of the Year” (CLAY) award. Brendan continued his work in the field of generic drugs as lead counsel for Nashville General Hospital (the Hospital Authority of Metropolitan Government of Nashville) in a class-action antitrust case against defendants for monopolizing enoxaparin, the generic version of the blockbuster life-saving anti-coagulant Lovenox, which in 2019, settled for $120 million, the second largest indirect-purchaser antitrust pharmaceutical settlement fund in history, after Cipro.
About Katharina Kolb
The Managing Partner of Lieff Cabraser’s Munich office, Dr. Katharina Kolb specializes in German and European competition law with a particular focus on litigation. Before joining Lieff Cabraser, Dr. Kolb worked as an attorney at another international law firm in Munich. Rankings like Who is Who Legal recognize Dr. Kolb as one of the world’s “Future Leaders” in competition law.